Dexcom (DXCM) Shares Outstanding (Diluted Average) (2013 - 2026)

Dexcom (DXCM) has 14 years of Shares Outstanding (Diluted Average) data on file, last reported at $393.6 million in Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) fell 3.41% year-over-year to $393.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $393.6 million (down 3.41% YoY) and the FY2025 annual result came in at $405.5 million, down 1.74% from the prior year.
• Shares Outstanding (Diluted Average) slipped to $393.6 million in Q1 2026 per DXCM's latest filing, from $405.5 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $431.5 million in Q2 2023 and bottomed at $393.6 million in Q1 2026.
• The 5-year median for Shares Outstanding (Diluted Average) is $416.8 million (2024), against an average of $416.8 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) surged 309.85%; it then decreased 4.23% in 2024.
• Tracing DXCM's Shares Outstanding (Diluted Average) over 5 years: stood at $427.5 million in 2022, then retreated by 0.47% to $425.5 million in 2023, then decreased by 3.01% to $412.7 million in 2024, then declined by 1.74% to $405.5 million in 2025, then declined by 2.93% to $393.6 million in 2026.
• Per Business Quant, the three latest DXCM Shares Outstanding (Diluted Average) figures stand at $393.6 million (Q1 2026), $405.5 million (Q4 2025), and $407.7 million (Q3 2025).

Peer Comparison